We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 14.00 | 0.93% | 1,520.00 | 1,508.00 | 1,511.00 | 1,515.00 | 1,480.00 | 1,506.00 | 696,766 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1.09B | 2M | 0.0148 | 1,019.59 | 2.04B |
From Apr 2019 to Apr 2024
TIDMINDV
RNS Number : 5861T
Indivior PLC
09 January 2017
Indivior PLC (the 'Company')
Shaun Thaxter, CEO of Indivior PLC is presenting at the JP Morgan Healthcare Conference on January 11(th) , 2017 at 4pm Pacific time (12am UK time). A link to the webcast of the presentation is provided and the slides can be downloaded in pdf format on the Company's website at www.indivior.com. In addition, a playback of the presentation will be available for 3 months.
About Indivior
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its robust, global opioid dependence portfolio, Indivior has a strong pipeline of product candidates designed to both expand treatments in opioid dependence and address other chronic diseases of addiction - including alcohol use disorder, cocaine intoxication and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio is available in over 40 countries worldwide. Its name is a fusion of the words individual and endeavor and its logo radiates the company's patient-centered holistic focus on expanding access to high-quality treatment services for addiction worldwide. For additional product information, please visit www.indivior.com
Investor Enquiries
Tom Corran, IR Director, Indivior PLC
+44 1753 423965
tom.corran@indivior.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSSAFMMFWSESF
(END) Dow Jones Newswires
January 09, 2017 08:00 ET (13:00 GMT)
1 Year Indivior Chart |
1 Month Indivior Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
